NASDAQ: DMACDiamedica Therapeutics Inc Stock
$5.63-0.02 (-0.35%)
Updated Jun 15, 2026
DMAC Price
$5.63
Fair Value Price
$0.33
Market Cap
$303.36M
52 Week Low
$3.48
52 Week High
$10.42
P/E
-7.93x
P/B
6.42x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$35.16M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
-$31M
Beta
0.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DMAC Overview
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DMAC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DMAC
Ranked#393 of 462
Ranked#393 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important DMAC news, forecast changes, insider trades & much more!
DMAC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DMAC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DMAC ($5.63) is overvalued by 1,616.76% relative to our estimate of its Fair Value price of $0.33 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DMAC ($5.63) is not significantly undervalued (1,616.76%) relative to our estimate of its Fair Value price of $0.33 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DMAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DMAC due diligence checks available for Premium users.
Valuation
DMAC fair value
Fair Value of DMAC stock based on Discounted Cash Flow (DCF)
Price
$5.63
Fair Value
$0.33
Overvalued by
1,616.76%
DMAC ($5.63) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DMAC ($5.63) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DMAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DMAC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.93x
Industry
16.41x
Market
14.3x
DMAC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.42x
Industry
4.89x
DMAC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DMAC's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.1M
Profit Margin
0%
DMAC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$53.1M
Liabilities
$5.8M
Debt to equity
0.12
DMAC's short-term assets ($52.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DMAC's short-term assets ($52.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DMAC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DMAC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.1M
Investing
-$2.1M
Financing
$417.0k
DMAC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DMAC vs Biotech Stocks
Diamedica Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.